Insights into the Mechanism of Action of Antipsychotic Drugs Derived from Animal Models: Standard of Care versus Novel Targets
- PMID: 37569748
- PMCID: PMC10418544
- DOI: 10.3390/ijms241512374
Insights into the Mechanism of Action of Antipsychotic Drugs Derived from Animal Models: Standard of Care versus Novel Targets
Abstract
Therapeutic intervention for schizophrenia relies on blockade of dopamine D2 receptors in the associative striatum; however, there is little evidence for baseline overdrive of the dopamine system. Instead, the dopamine system is in a hyper-responsive state due to excessive drive by the hippocampus. This causes more dopamine neurons to be in a spontaneously active, hyper-responsive state. Antipsychotic drugs alleviate this by causing depolarization block, or excessive depolarization-induced dopamine neuron inactivation. Indeed, both first- and second-generation antipsychotic drugs cause depolarization block in the ventral tegmentum to relieve positive symptoms, whereas first-generation drugs also cause depolarization in the nigrostriatal dopamine system to lead to extrapyramidal side effects. However, by blocking dopamine receptors, these drugs are activating multiple synapses downstream from the proposed site of pathology: the loss of inhibitory influence over the hippocampus. An overactive hippocampus not only drives the dopamine-dependent positive symptoms, but via its projections to the amygdala and the neocortex can also drive negative and cognitive symptoms, respectively. On this basis, a novel class of drugs that can reverse schizophrenia at the site of pathology, i.e., the hippocampal overdrive, could be effective in alleviating all three classes of symptoms of schizophrenia while also being better tolerated.
Keywords: antipsychotic; dopamine; schizophrenia.
Conflict of interest statement
A.A.G. received funds from the following organizations: Lundbeck, Pfizer, Otsuka, Asubio, Autofony, Janssen, Alkermes, SynAgile, Merck, and Newron. DU declares no competing interest.
Figures



Similar articles
-
Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia.J Neurosci. 2011 Aug 24;31(34):12330-8. doi: 10.1523/JNEUROSCI.2808-11.2011. J Neurosci. 2011. PMID: 21865475 Free PMC article.
-
The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia.J Neural Transm Suppl. 1992;36:91-131. doi: 10.1007/978-3-7091-9211-5_6. J Neural Transm Suppl. 1992. PMID: 1356143 Review.
-
Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs.Trends Neurosci. 1997 Jan;20(1):31-7. doi: 10.1016/S0166-2236(96)10064-3. Trends Neurosci. 1997. PMID: 9004417 Review.
-
Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia.Neuropharmacology. 2020 Feb;163:107632. doi: 10.1016/j.neuropharm.2019.05.009. Epub 2019 May 8. Neuropharmacology. 2020. PMID: 31077730 Free PMC article. Review.
-
Atypical antipsychotics: mechanism of action.Can J Psychiatry. 2002 Feb;47(1):27-38. Can J Psychiatry. 2002. PMID: 11873706 Review.
Cited by
-
Serotonin and schizophrenia: what influences what?Front Psychiatry. 2024 Oct 17;15:1451248. doi: 10.3389/fpsyt.2024.1451248. eCollection 2024. Front Psychiatry. 2024. PMID: 39483729 Free PMC article. No abstract available.
-
The Formation and Function of the VTA Dopamine System.Int J Mol Sci. 2024 Mar 30;25(7):3875. doi: 10.3390/ijms25073875. Int J Mol Sci. 2024. PMID: 38612683 Free PMC article. Review.
-
The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia.Biochem Pharmacol. 2024 Oct;228:116298. doi: 10.1016/j.bcp.2024.116298. Epub 2024 May 21. Biochem Pharmacol. 2024. PMID: 38782077 Review.
-
Functional properties of corticothalamic circuits targeting paraventricular thalamic neurons.Neuron. 2024 Dec 18;112(24):4060-4080.e7. doi: 10.1016/j.neuron.2024.10.010. Epub 2024 Nov 5. Neuron. 2024. PMID: 39504962
-
The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity.Pharmaceuticals (Basel). 2024 Apr 3;17(4):461. doi: 10.3390/ph17040461. Pharmaceuticals (Basel). 2024. PMID: 38675421 Free PMC article. Review.
References
-
- Miller P., Lawrie S.M., Hodges A., Clafferty R., Cosway R., Johnstone E.C. Genetic liability, illicit drug use, life stress and psychotic symptoms: Preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Soc. Psychiatry Psychiatr. Epidemiol. 2001;36:338–342. doi: 10.1007/s001270170038. - DOI - PubMed
-
- Berthelot N., Garon-Bissonnette J., Jomphe V., Doucet-Beaupré H., Bureau A., Maziade M. Childhood trauma may increase risk of psychosis and mood disorder in genetically high-risk children and adolescents by enhancing the accumulation of risk indicators. Schizophr. Bull. Open. 2022;3:sgac017. doi: 10.1093/schizbullopen/sgac017. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical